Christine Lovly
-
Study reveals need for matching targeted therapies with EGFR subtypes
A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers. Read MoreJul 28, 2022
-
Vanderbilt researchers present new data on clinical trials at ASCO 2021
Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year. Read MoreMay 26, 2021
-
Personalized Structural Biology aids cancer treatment decisions
Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level. Read MoreApr 8, 2021
-
Investigators map genomic landscape of very rare cancer
A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer. Read MoreFeb 28, 2019
-
Lung cancer patients and advocates visit VUMC research labs
A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease. Read MoreJun 14, 2018
-
Lovly earns scholarship grant for lung cancer research
Christine Lovly, MD, PhD, assistant professor of Medicine at Vanderbilt, has received a $200,000 grant to support promising new research on lung cancer. Read MoreMar 8, 2018
-
Liquid biopsies help reveal lung cancer mutations
Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center (VICC) have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC). Read MoreNov 2, 2017
-
VU scientists discuss cancer treatments, cellular dynamics
A trio of Vanderbilt University scientists described their cutting-edge investigations of cellular dynamics and cancer treatment during last week’s Flexner Discovery Lecture. Read MoreSep 28, 2017
-
Trio of Vanderbilt scientists set for Discovery Lecture
Three Vanderbilt University scientists on the forefront of research in cellular dynamics and cancer treatment will discuss their cutting-edge investigations during the next Flexner Discovery Lecture on Thursday, Sept. 21. Read MoreSep 14, 2017
-
Lovly elected to American Society for Clinical Investigation
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt, has been elected to The American Society for Clinical Investigation (ASCI). Read MoreMay 4, 2017
-
Vanderbilt’s Christine Lovly elected to American Society for Clinical Investigation
Christine Lovly, Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology at Vanderbilt University Medical Center (VUMC), has been elected to The American Society for Clinical Investigation (ASCI). The ASCI is an elite honor society of physician-scientists. The Society, founded in 1908,… Read MoreApr 24, 2017
-
VICC trial putting lung cancer therapy to the test
Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. Read MoreOct 20, 2016
-
Lovly tapped to brief Congress on cancer research
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science. Read MoreJun 22, 2016
-
Precision medicine already changing cancer treatment strategies
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. Read MoreMay 26, 2016
-
Endowed fellowships help create personal connections
When former Nashvillian Carol O’Hare speaks about a specific group of physicians at Vanderbilt-Ingram Cancer Center (VICC), her voice softens, and she refers to them affectionately as “my fellows.” Read MoreMay 12, 2016
-
Lovly lands cancer research grant from V Foundation
Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been awarded a V Scholar Grant from the V Foundation for Cancer Research. Read MoreJan 21, 2016
-
VICC helps expand cancer patient’s treatment options
Edward (Ned) Wikle recently celebrated the Christmas holidays with his wife and three young children, a celebration the Jackson, Mississippi-based endodontist, U.S. Navy veteran and cancer patient wasn’t sure he would have. Read MoreJan 14, 2016
-
Gene mutations may predict melanoma response to immunotherapies
Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators. Read MoreMar 12, 2015
-
Lung cancer study reveals new drug combination targets
A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways. Read MoreSep 4, 2014
-
Lovly’s research bolstered by lung cancer foundation
The LUNGevity Foundation has awarded a 2014 Career Development Award for Translational Research to Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology. Read MoreJul 17, 2014